Why the study?
Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet therapy in patients undergoing percutaneous coronary intervention were limited.
Does P2Y12 inhibitor monotherapy after 3 months of DAPT compared with 12 months of DAPT prevent major adverse cardiac and cerebrovascular events in patients undergoing PCI with drug-eluting stents?
Population
2993 patients undergoing PCI with drug-eluting stents in Korea
Comparison
P2Y12 inhibitor monotherapy after 3 months DAPT vs 12 months DAPT
Design
Multicenter open-label noninferiority randomized trial
Follow-up
12 months
Authors
Loading...
Supports shorter DAPT post-PCI without excess ischemic events; extends evidence for P2Y12 monotherapy de-escalation strategies.
Does P2Y12 inhibitor monotherapy after 3 months of DAPT compared with 12 months of DAPT prevent major adverse cardiac and cerebrovascular events in patients undergoing PCI with drug-eluting stents?
In patients undergoing PCI with drug-eluting stents, dropping aspirin after 3 months to continue P2Y12 inhibitor monotherapy is noninferior to 12 months of DAPT for ischemic events and significantly reduces bleeding.
Hahn et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: